Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study.

Completed

Phase N/A Results

Results

The analysis took into account all 212 randomized patients and showed no statistically significant difference between the enoxaprin and UFH groups. The absolute difference in event rates was 11.3% (p=0.127, Fisher’s exact test, twotailed) in favor of the enoxaparin group. Seventeen percent of the UFH group, compared to 8.5% of the enoxaprin group had adverse treatment-related events. Bleeding complications were experienced by 2.8% (3/106) of patients in the enoxaparin group and 1.9% (2/106) of patients in the UFH group.